Show simple item record

dc.contributor.authorMerriel, SWD
dc.contributor.authorHetherington, L
dc.contributor.authorSeggie, A
dc.contributor.authorCastle, JT
dc.contributor.authorCross, W
dc.contributor.authorRoobol, MJ
dc.contributor.authorGnanapragasam, V
dc.contributor.authorMoore, CM
dc.contributor.authorAshworth, M
dc.contributor.authorBradley, E
dc.contributor.authorCass, K
dc.contributor.authorCornford, P
dc.contributor.authorKeanie, J
dc.contributor.authorLittle, S
dc.contributor.authorMastris, K
dc.contributor.authorNairn, A
dc.contributor.authorOxley, J
dc.contributor.authorParker, C
dc.contributor.authorPatel, A
dc.contributor.authorPorter, R
dc.contributor.authorPowell, L
dc.contributor.authorRichenberg, J
dc.contributor.authorRoland, M
dc.contributor.authorVarma, M
dc.contributor.authorVictor, D
dc.contributor.authorWaymont, C
dc.date.accessioned2019-11-01T10:00:13Z
dc.date.issued2019-02-11
dc.description.abstractObjectives: To develop a consensus statement on current best practice of active surveillance (AS) in the UK, informed by patients and clinical experts. Subjects and Methods: A consensus statement was drafted on the basis of three sources of data: systematic literature search of national and international guidelines; data arising from a Freedom of Information Act request to UK urology departments regarding their current practice of AS; and survey and interview responses from men with localized prostate cancer regarding their experiences and views of AS. The Prostate Cancer UK Expert Reference Group (ERG) on AS was then convened to discuss and refine the statement. Results: Guidelines and protocols for AS varied significantly in terms of risk stratification, criteria for offering AS, and protocols for AS between and within countries. Patients and healthcare professionals identified clinical, emotional and process needs for AS to be effective. Men with prostate cancer wanted more information and psychological support at the time of discussing AS with the treating team and in the first 2 years of AS, and a named healthcare professional to discuss any questions or concerns they had. The ERG agreed 30 consensus statements regarding best practice for AS. Statements were grouped under headings: ‘Inclusion/Exclusion Criteria’; ‘AS follow-up protocol’ and ‘When to stop AS’. Conclusion: Significant variation currently exists in the practice of AS in the UK and internationally. Men have clear views on the level of involvement in treatment decisions and support from their treating professionals when receiving AS. The Prostate Cancer UK AS ERG has developed a set of consensus statements for best practice in AS. Evidence for best practice in AS, and the use of multiparametric magnetic resonance imaging in AS, is still evolving, and further studies are needed to determine how to optimize AS outcomes.en_GB
dc.description.sponsorshipProstate Cancer UKen_GB
dc.identifier.citationVol. 124 (1), pp. 47 - 54en_GB
dc.identifier.doi10.1111/bju.14707
dc.identifier.urihttp://hdl.handle.net/10871/39451
dc.language.isoenen_GB
dc.publisherWiley for British Association of Urological Surgeons (BAUS)en_GB
dc.rights© 2019 The Authors BJU International Published by John Wiley & Sons Ltd on behalf of BJU International. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.en_GB
dc.subjectactive surveillanceen_GB
dc.subjectclinical consensusen_GB
dc.subjectguidelinesen_GB
dc.subject#PCSMen_GB
dc.subject#ProstateCanceren_GB
dc.subject#urooncen_GB
dc.titleBest practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statementen_GB
dc.typeArticleen_GB
dc.date.available2019-11-01T10:00:13Z
dc.identifier.issn1464-4096
dc.descriptionThis is the final version. Available on open access from Wiley via the DOI in the record.en_GB
dc.identifier.journalBJU Internationalen_GB
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/en_GB
dcterms.dateAccepted2019-02-10
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2019-02-11
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2019-10-30T15:40:32Z
refterms.versionFCDVoR
refterms.dateFOA2019-11-01T10:00:19Z
refterms.panelAen_GB
refterms.depositExceptionpublishedGoldOA


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2019 The Authors BJU International Published by John Wiley & Sons Ltd on behalf of BJU International.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Except where otherwise noted, this item's licence is described as © 2019 The Authors BJU International Published by John Wiley & Sons Ltd on behalf of BJU International. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.